<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Mov Disord</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Mov Disord</journal-id><journal-title-group><journal-title>Journal of Clinical Movement Disorders</journal-title></journal-title-group><issn pub-type="epub">2054-7072</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28852567</article-id><article-id pub-id-type="pmc">5568719</article-id><article-id pub-id-type="publisher-id">62</article-id><article-id pub-id-type="doi">10.1186/s40734-017-0062-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>A C</italic>omputerized <italic>Co</italic>gnitive behavioral therapy <italic>R</italic>andomized, Controlle<italic>d</italic>, pilot trial for insomnia in <italic>P</italic>arkinson <italic>D</italic>isease (<italic>ACCORD-PD</italic>)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Patel</surname><given-names>Shnehal</given-names></name><address><phone>412-448-5844</phone><email>Patels7@ccf.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ojo</surname><given-names>Oluwadamilola</given-names></name><address><email>drlaraoyatoye@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Genc</surname><given-names>Gencer</given-names></name><address><email>gencerg@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Oravivattanakul</surname><given-names>Srivadee</given-names></name><address><email>srivadee@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Huo</surname><given-names>Yang</given-names></name><address><email>yanghuo2008@sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rasameesoraj</surname><given-names>Tanaporn</given-names></name><address><email>rasamet@ccf.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lu</given-names></name><address><email>WangL8@ccf.org</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bena</surname><given-names>James</given-names></name><address><email>benaj@ccf.org</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Drerup</surname><given-names>Michelle</given-names></name><address><email>drerupm@ccf.org</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Foldvary-Schaefer</surname><given-names>Nancy</given-names></name><address><email>foldvan@ccf.org</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ahmed</surname><given-names>Anwar</given-names></name><address><email>ahmeda@ccf.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fernandez</surname><given-names>Hubert H.</given-names></name><address><email>fernanh@ccf.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>9500 Euclid Ave/U2, Cleveland, OH 44195 USA </aff><aff id="Aff2"><label>2</label>9500 Euclid Ave/JJN3, Cleveland, OH 44195 USA </aff><aff id="Aff3"><label>3</label>9500 Euclid Ave/P57, Cleveland, OH 44195 USA </aff><aff id="Aff4"><label>4</label>9500 Euclid Ave, Cleveland, OH 44195 USA </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>4</volume><elocation-id>16</elocation-id><history><date date-type="received"><day>20</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Parkinson disease (PD) is associated with a high prevalence of insomnia, affecting up to 88% of patients. Pharmacotherapy studies in the literature addressing insomnia in PD reveal disappointing and inconsistent results. Cognitive behavioral therapy (CBT) is a novel treatment option with durable effects shown in primary insomnia. However, the lack of accessibility and expense can be limiting. For these reasons, computerized CBT for insomnia (CCBT-I) has been developed. The CCBT-I program is a 6-week web-based course consisting of daily &#x0201c;lessons&#x0201d; providing learnable skills and appropriate recommendations to help patients improve their sleep habits and patterns.</p></sec><sec><title>Methods</title><p id="Par2">We conducted a single-center, pilot, randomized controlled trial comparing CCBT-I versus standardized sleep hygiene instructions to treat insomnia in PD. Twenty-eight subjects with PD experiencing insomnia, with a score&#x000a0;&#x0003e;&#x000a0;11 on the Insomnia Severity Index (ISI) were recruited. Based on a 6-point improvement in ISI in treatment group when compared to controls and an alpha&#x000a0;=&#x000a0;0.05 and beta of 0.1 (power&#x000a0;=&#x000a0;90%) a sample size of 11 patients (on active treatment) were required to detect this treatment effect using a dependent sample t-test.</p></sec><sec><title>Results</title><p id="Par3">In total, 8/14 (57%) subjects randomized to CCBT-I versus 13/14 (93%) subjects randomized to standard education completed the study. Among completers, the improvement in ISI scores was greater with CCBT-I as compared to standard education (&#x02212;7.9 vs &#x02212;3.5; <italic>p</italic>&#x000a0;=&#x000a0;0.03). However, in an intention-to-treat analysis, where all enrolled subjects were included, the change in ISI between groups was not significant (&#x02212;.4.5 vs &#x02212;3.3; <italic>p</italic>&#x000a0;=&#x000a0;0.48), likely due to the high dropout rate in the CCBT-I group (43%).</p></sec><sec><title>Conclusion</title><p id="Par4">This pilot study suggests that CCBT-I can be an effective treatment option for PD patients with insomnia when the course is thoroughly completed. High drop-out rate in our study shows that although effective, it may not be a generalizable option; however, larger studies are needed for further evaluation.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par18">Parkinson Disease (PD) is associated with a high prevalence of sleep complaints, including insomnia, daytime sleepiness, sleep apnea, restless legs syndrome (RLS) and REM sleep behavior disorder (RBD) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The most common sleep disturbance in patients with PD is sleep maintenance insomnia, affecting up to 88% of patients [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Sleep maintenance insomnia is characterized by a decrease in total sleep time (TST) and an increase in the number of arousals and awakenings after sleep onset. Sleep initiation insomnia affects 23% to 30% of PD patients [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. However, in controlled studies, the prevalence of sleep initiation insomnia was found to be comparable among PD patients and healthy elderly controls.</p><p id="Par19">Insomnia therapy in PD has primarily consisted of pharmacotherapy using non-benzodiazepine hypnotics, sedating antipsychotics (such as quetiapine), and benzodiazepines. However, side effects, tolerance and dependency, cognitive impairment, and decreased effectiveness over time limit their use. Cognitive behavioral therapy for insomnia (CBT-I) has been shown to be more effective than pharmacotherapy long-term in primary insomnia cohorts and the NIH State-of-the-Science conference Statement identified it as the first-line approach to insomnia treatment [<xref ref-type="bibr" rid="CR7">7</xref>]. CBT-I helps identify and modify negative thoughts about sleep and behaviors that perpetuate insomnia [<xref ref-type="bibr" rid="CR8">8</xref>]. However, widespread use of CBT-I has been limited by lack of trained clinicians, geographical remoteness of the trained providers, stigmatization of receiving psychological service and expense. For these reasons, computerized cognitive behavioral therapy for insomnia (CCBT-I), has been developed in order to make CBT-I more convenient. The Cleveland Clinic CCBT-I program [<xref ref-type="bibr" rid="CR9">9</xref>] consists of sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relaxation training delivered in stages over a 6-week period [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. The efficacy of CCBT-I for primary insomnia has been demonstrated in several randomized controlled trials [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par20">Despite the high prevalence and life-quality impact of insomnia in PD, there are only a few pharmacotherapy studies specifically addressing insomnia without a focus on nocturnal motor symptoms [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Most recently, a three-arm six-week randomized pilot study comparing non-pharmacologic treatment (cognitive behavioral therapy/bright light therapy) versus doxepin 10&#x000a0;mg at bedtime versus inactive placebo, was published [<xref ref-type="bibr" rid="CR22">22</xref>]. Although it was found that doxepin and non-pharmacologic treatment substantially improved insomnia, we are aware of no study on CCBT-I which provides near universal access to this patient population. Therefore, we have conducted a pilot study evaluating the effect of CCBT-I on insomnia in PD patients.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par21">This was a 6-week pilot randomized (1:1 ratio), parallel-group, controlled study evaluating effectiveness of CCBT-I in PD patients by measuring clinical and sleep variables before and after completion of the program. PD patients with insomnia were asked to participate at their clinical visit by their current movement disorder provider. If the patient was interested, the research coordinator or investigator discussed study further with patient. Subjects meeting inclusion criteria (Table <xref rid="Tab1" ref-type="table">1</xref>) were randomized to CCBT-I or standard sleep hygiene education (Table <xref rid="Tab2" ref-type="table">2</xref>). Randomization was done by study coordinator who made 28 sealed envelopes containing their group designation. Once patients signed the informed consent form, they were given the sealed envelope containing their group designation.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inclusion and Exclusion Criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th>
<italic>Inclusion Criteria</italic>
</th><th>
<italic>Exclusion Criteria</italic>
</th></tr></thead><tbody><tr><td>1. 35&#x02013;85&#x000a0;years of age</td><td>1. Dementia as defined by DSM-IV criteria</td></tr><tr><td>2. Diagnosis of PD by a Movement Disorders neurologist</td><td>2. Patients with suboptimally treated depression and significant depressive symptoms as defined by a PHQ-9 score of &#x0003e; 15. Antidepressant medications prescribed for depression or anxiety were allowed if the patient had been on a stable dose for at least 1&#x000a0;month.</td></tr><tr><td>3. On stable antiparkinsonian medications for the past 30&#x000a0;days</td><td>3. Significant hallucinations or psychotic symptoms requiring antipsychotic medications</td></tr><tr><td>4. ISI&#x000a0;&#x0003e;&#x000a0;11</td><td>4. Presence of significant sleep disorders that could be contributing to insomnia such as known sleep apnea, RBD, RLS</td></tr><tr><td>5. Access to a computer and internet</td><td>5. Presence of significant motor fluctuations, especially nocturnal akinesias that could be contributing to insomnia</td></tr><tr><td>6. Be able to speak, read and understand English</td><td>6. Use of sedatives, benzodiazepines or sedating antidepressants (such as mirtazapine, TCAs), modafinil, stimulants, anticholinergic medications, were allowed if the patient had been on a stable dose for at least 1&#x000a0;month and was not taking it as a sleep aid.</td></tr><tr><td/><td>7. Significant renal, hepatic, cardiac and thyroid disease that could have interfered with protocol adherence</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Sleep Hygiene Education</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>BEFORE GETTING INTO BED:</td></tr><tr><td>&#x02003;-Do not eat a heavy meal close to bedtime (a light bedtime snack is OK),</td></tr><tr><td>&#x02003;-Create a positive sleep environment &#x02013; cool, dark and quiet,</td></tr><tr><td>&#x02003;-Create a buffer zone &#x02013; quiet time prior to bed time. During this time, you should do things that are enjoyable on their own rather than activities that are goal oriented.</td></tr><tr><td>WHILE IN BED:</td></tr><tr><td>&#x02003;-Avoid watching the clock. Turn your clock around (or cover it) and use your alarm if needed.</td></tr><tr><td>&#x02003;-Use your bed only for sleep and sex &#x02013; Avoid TV watching, use of computer, reading, or cell phone use in bed.</td></tr><tr><td>IN THE MORNING AND DURING THE DAYTIME:</td></tr><tr><td>&#x02003;-Avoid naps during the day.</td></tr><tr><td>&#x02003;-Limit caffeine and consume before noon.</td></tr><tr><td>&#x02003;-Exercise regularly but not within 3&#x02013;4&#x000a0;h of bedtime.</td></tr></tbody></table></table-wrap>
</p><p id="Par22">Subjects completed questionnaires at baseline, 8 and 12&#x000a0;weeks after randomization, including:<list list-type="order"><list-item><p id="Par23">Epworth Sleepiness Scale (ESS) &#x02014;The ESS is a 4-point scale (0&#x02013;3) measuring daytime sleepiness of a patient in 8 different situations or activities that most people engage in as part of their daily lives, although not necessarily every day. The total ESS score can range between 0 and 24. The higher the score, the higher the person&#x02019;s level of daytime sleepiness [<xref ref-type="bibr" rid="CR23">23</xref>].</p></list-item><list-item><p id="Par24">Pittsburgh Insomnia Rating Scale (PIRS20) &#x02014;PIRS20 is a subjective measurement of the severity of insomnia that the patient rates [<xref ref-type="bibr" rid="CR24">24</xref>].</p></list-item><list-item><p id="Par25">Insomnia Severity Index (ISI) &#x02014;ISI is a valid and reliable tool to diagnose and measure severity of insomnia. It consists of 7 questions concerning sleep onset, sleep maintenance, early awakening, level of satisfaction with sleep pattern, extent of interference with daily functioning, conspicuousness of impairment caused by sleep problem, and level of concern about current sleep problem. Each item is marked on a 5-point Likert scale (0 to 4). Total scores after evaluation ranges from 0 to 28; the higher score, the more insomnia severity. Scores 0 to 7 indicate no clinically significant insomnia, 8 to 14 sub-threshold insomnia, 15 to 21 clinically significant insomnia (moderate), and 22 to 28 clinically significant insomnia (severe) [<xref ref-type="bibr" rid="CR25">25</xref>].</p></list-item><list-item><p id="Par26">Fatigue Severity Scale (FSS) &#x02014;FSS measures fatigue severity by measuring its effect on daily activities in patients with chronic neurologic disorders. It is measured on a 7-point scale (0&#x02013;7), higher the score indicating more severe fatigue [<xref ref-type="bibr" rid="CR26">26</xref>].</p></list-item><list-item><p id="Par27">Unified Parkinson Disease Rating Scale (UPDRS) parts 1b and II&#x02014;UPDRS 1b and II measure activities of daily living in PD evaluating motor and non-motor features. It is a 20-question survey, each question with a 0&#x02013;4 scale, the higher the score, the more severe the impact on the particular activity. When analysing the data, we modified the score by removing the question related to sleep to evaluate if the score change in a patient&#x02019;s activities of daily living that wasn&#x02019;t swayed by improvement in sleep.</p></list-item><list-item><p id="Par28">Patient Health Questionnaire (PHQ-9)&#x02014;The PHQ-9 is a multipurpose instrument for screening, diagnosing, and measuring severity of depression. The score ranges from 5 to 20, with the higher score suggesting more severe depression [<xref ref-type="bibr" rid="CR27">27</xref>].</p></list-item><list-item><p id="Par29">Parkinson Disease Questionnaire (PDQ8)&#x02014;PDQ8 is an 8-question self-administered questionnaire, used to measure quality of life in persons with Parkinson&#x02019;s disease. Scores range from 0 to 4, the higher the score, the greater the impairment on the person&#x02019;s quality of life. The 39-point PDQ provides scores for each of the 8 domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communications and bodily discomfort. Alternatively, the sum of the domain scores can be used to assess the overall health-related quality of life profile of the individual questioned [<xref ref-type="bibr" rid="CR28">28</xref>].</p></list-item></list>
</p><sec id="Sec3"><title>CCBT-I therapy</title><p id="Par30">Go! To Sleep is a 6-week online, interactive CBT-I based program designed to foster better sleep habits and help participants implement cognitive behavioral therapy for insomnia strategies. Subjects were provided with a unique password to access the program. Daily program access is encouraged via daily email reminders to complete a sleep log based on prior night&#x02019;s sleep pattern. After completing sleep log, the user is given individualized feedback based on their sleep log responses as well as a daily sleep efficiency score to help them track their progress through the program. There are daily &#x0201c;lessons&#x0201d; or articles that provide psychoeducation regarding insomnia and strategies to help address their sleep concerns. In addition, throughout the program they have access to relaxation/meditation practices as well as other strategies designed to improve stress management and sleep. There is a mobile application for easy sleep tracking.</p><p id="Par31">Table <xref rid="Tab2" ref-type="table">2</xref> shows the sleep hygiene advice that was given to the control group.</p><p id="Par32">All subjects received weekly telephone reminders from an investigator to participate in their assigned therapy. Additional telephone calls were made 8 and 12&#x000a0;weeks after randomization to complete the questionnaires and return to the investigators in self-addressed envelopes. Subjects were considered a dropout if they could not complete CCBT-I or if they did not return the week 8 questionnaires.</p><p id="Par33">The Institutional Review Board of the Cleveland Clinic approved the project.</p></sec><sec id="Sec4"><title>Statistical methods</title><p id="Par34">CCBT-I has never been tested in the PD population, thus we did not have prior experience from which to perform sample size calculations. However, there is a study using ISI and advocating for a 6-point change as significant [<xref ref-type="bibr" rid="CR29">29</xref>]. This study gives population mean value for ISI as 19.7 with standard deviation as 4.1. Another study examining the validation of the ISI as an outcome measure for insomnia research showed population mean value for ISI as 17.9 with standard deviation as 4.1 [<xref ref-type="bibr" rid="CR30">30</xref>]. In a three-arm (cognitive behavioral therapy/bright light therapy versus doxepin versus inactive placebo), six-week, randomized study, the baseline ISI was 14.7&#x000a0;&#x000b1;&#x000a0;6.1, 19.9&#x000a0;&#x000b1;&#x000a0;3.7 and 16.5&#x000a0;&#x000b1;&#x000a0;5.4 [<xref ref-type="bibr" rid="CR22">22</xref>]. Based on a 6-point improvement in ISI in treatment group when compared to controls and an alpha&#x000a0;=&#x000a0;0.05 and beta of 0.1 (power&#x000a0;=&#x000a0;90%) a sample size of 11 patients (on active treatment) were required to detect this treatment effect using a dependent sample t-test. Assuming a dropout rate of 25%, a sample size of 14 patients on each arm were recruited.</p><p id="Par35">The data are presented as mean&#x000a0;&#x000b1;&#x000a0;standard deviation for continuous variables and N (%) for categorical variables. Comparison of demographic variables was performed by two-sample t test in continuous variables, and chi-square test or Fisher exact test in categorical variables. Change from baseline to end point was analyzed using paired t test; and compared between cases and controls by two-sample t test.</p><p id="Par36">To account for the correlation among repeated measures on the same subject a mixed model assuming compound symmetry correlation structure was used to test the trend from Week 1 to Week 6 of the online program. Least square means with 95% confidence intervals were presented to show the trend. Analyses were performed based on an overall significance level of 0.05, using SAS software (version 9.4, Cary, NC).</p></sec></sec><sec id="Sec5"><title>Results</title><p id="Par37">Twenty-nine subjects were screened for enrollment. One subject was not considered a candidate after screening due to low ISI score. Subsequently, 28 subjects were randomized, 14 in each group. Sample characteristics are shown in Table <xref rid="Tab3" ref-type="table">3</xref>. There were no significant differences between groups except for gender, where there were more males in the CCBT-I group than in the control group.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Baseline Characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Case</th><th>Control</th><th>
<italic>p</italic>-value</th></tr></thead><tbody><tr><td>Age (years)</td><td>63.1&#x000a0;&#x000b1;&#x000a0;6.8</td><td>64.7&#x000a0;&#x000b1;&#x000a0;9.5</td><td>0.62<sup>a</sup>
</td></tr><tr><td>Gender</td><td/><td/><td>
<bold><italic>0.022</italic></bold>
<sup><bold><italic>c</italic></bold></sup>
</td></tr><tr><td>&#x02003;Female</td><td>3(21.4)</td><td>9(64.3)</td><td/></tr><tr><td>&#x02003;Male</td><td>11(78.6)</td><td>5(35.7)</td><td/></tr><tr><td>ESS Total</td><td>11.1&#x000a0;&#x000b1;&#x000a0;4.9</td><td>9.3&#x000a0;&#x000b1;&#x000a0;6.2</td><td>0.39<sup>a</sup>
</td></tr><tr><td>FSS Total</td><td>27.3&#x000a0;&#x000b1;&#x000a0;13.1</td><td>29.1&#x000a0;&#x000b1;&#x000a0;12.2</td><td>0.72<sup>a</sup>
</td></tr><tr><td>ISI Total</td><td>15.7&#x000a0;&#x000b1;&#x000a0;3.0</td><td>15.4&#x000a0;&#x000b1;&#x000a0;2.9</td><td>0.80<sup>a</sup>
</td></tr><tr><td>UPDRS1b Total</td><td>9.8&#x000a0;&#x000b1;&#x000a0;4.0</td><td>9.4&#x000a0;&#x000b1;&#x000a0;2.1</td><td>0.71<sup>a</sup>
</td></tr><tr><td>UPDRS1b Modified</td><td>5.4&#x000a0;&#x000b1;&#x000a0;3.4</td><td>5.1&#x000a0;&#x000b1;&#x000a0;2.0</td><td>0.79<sup>a</sup>
</td></tr><tr><td>UPDRS2 total</td><td>12.6&#x000a0;&#x000b1;&#x000a0;7.9</td><td>10.4&#x000a0;&#x000b1;&#x000a0;7.1</td><td>0.46<sup>a</sup>
</td></tr><tr><td>PDQ Total</td><td>14.4&#x000a0;&#x000b1;&#x000a0;4.4</td><td>15.2&#x000a0;&#x000b1;&#x000a0;5.8</td><td>0.70<sup>a</sup>
</td></tr><tr><td>PHQ9 Total</td><td>7.8&#x000a0;&#x000b1;&#x000a0;5.1</td><td>7.2&#x000a0;&#x000b1;&#x000a0;4.2</td><td>0.73<sup>a</sup>
</td></tr><tr><td>pirs20 Total</td><td>9.1&#x000a0;&#x000b1;&#x000a0;2.4</td><td>9.1&#x000a0;&#x000b1;&#x000a0;2.1</td><td>0.92<sup>a</sup>
</td></tr><tr><td>EQ5D Index</td><td>0.75&#x000a0;&#x000b1;&#x000a0;0.15</td><td>0.79&#x000a0;&#x000b1;&#x000a0;0.13</td><td>0.46<sup>a</sup>
</td></tr></tbody></table><table-wrap-foot><p>
<italic>p</italic>-values: <sup>a</sup>two-sample <italic>t</italic> test, <sup>c</sup>Pearson's chi-square test</p><p>Bold values are statistically significant <italic>p</italic> &#x0003c; 0.05</p></table-wrap-foot></table-wrap>
</p><p id="Par38">Six subjects in the treatment group and 1 in the control group withdrew from the study. Using intention-to-treat analysis, the last available data point was used as endpoint.</p><p id="Par39">Intention-to-treat analysis showed a significant improvement in ISI (<italic>p</italic>&#x000a0;=&#x000a0;0.007), ESS (<italic>p</italic>&#x000a0;=&#x000a0;0.048) and PIRS20 (<italic>p</italic>&#x000a0;=&#x000a0;0.004) and PHQ-9 (<italic>p</italic>&#x000a0;=&#x000a0;0.011) scores in the treatment group when compared to the respective scores prior to CCBT-I treatment, as shown in Table <xref rid="Tab4" ref-type="table">4</xref>. UPDRS1b scores also significantly improved after treatment, however when modifying the score by removing the sleep variables, the change was no longer significant. However, when comparing the treatment group to the control group, none of these changes were significant, including ISI (&#x02212;4.5 vs &#x02212;3.3; <italic>p</italic>&#x000a0;=&#x000a0;0.48).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Baseline and endpoint scores per an Intention to Treat Analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Case(<italic>N</italic>&#x000a0;=&#x000a0;14)</th><th colspan="3">Control(<italic>N</italic>&#x000a0;=&#x000a0;14)</th></tr><tr><th>Factor</th><th>Baseline</th><th>Endpoint</th><th>
<italic>P</italic> value</th><th>Baseline</th><th>Endpoint</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>ESS Total</td><td>11.1&#x000a0;&#x000b1;&#x000a0;4.9</td><td>9.5&#x000a0;&#x000b1;&#x000a0;5.8</td><td>
<bold><italic>0.048</italic></bold>
</td><td>9.3&#x000a0;&#x000b1;&#x000a0;6.2</td><td>8.1&#x000a0;&#x000b1;&#x000a0;4.8</td><td>0.25</td></tr><tr><td>FSS Total</td><td>27.3&#x000a0;&#x000b1;&#x000a0;13.1</td><td>25.4&#x000a0;&#x000b1;&#x000a0;13.6</td><td>0.20</td><td>29.1&#x000a0;&#x000b1;&#x000a0;12.2</td><td>29.2&#x000a0;&#x000b1;&#x000a0;12.6</td><td>0.70</td></tr><tr><td>ISI Total</td><td>15.7&#x000a0;&#x000b1;&#x000a0;3.0</td><td>11.2&#x000a0;&#x000b1;&#x000a0;5.6</td><td>
<bold><italic>0.007</italic></bold>
</td><td>15.4&#x000a0;&#x000b1;&#x000a0;2.9</td><td>12.2&#x000a0;&#x000b1;&#x000a0;5.1</td><td>
<bold><italic>0.008</italic></bold>
</td></tr><tr><td>UPDRS1b Total</td><td>9.8&#x000a0;&#x000b1;&#x000a0;4.0</td><td>8.1&#x000a0;&#x000b1;&#x000a0;4.2</td><td>
<bold><italic>0.010</italic></bold>
</td><td>9.4&#x000a0;&#x000b1;&#x000a0;2.1</td><td>8.4&#x000a0;&#x000b1;&#x000a0;2.5</td><td>
<bold><italic>0.043</italic></bold>
</td></tr><tr><td>UPDRS1b Modified</td><td>5.4&#x000a0;&#x000b1;&#x000a0;3.4</td><td>5.0&#x000a0;&#x000b1;&#x000a0;3.2</td><td>0.34</td><td>5.1&#x000a0;&#x000b1;&#x000a0;2.0</td><td>4.9&#x000a0;&#x000b1;&#x000a0;1.7</td><td>0.58</td></tr><tr><td>UPDRS2 total</td><td>12.6&#x000a0;&#x000b1;&#x000a0;7.9</td><td>12.5&#x000a0;&#x000b1;&#x000a0;7.0</td><td>0.93</td><td>10.4&#x000a0;&#x000b1;&#x000a0;7.1</td><td>10.2&#x000a0;&#x000b1;&#x000a0;8.0</td><td>0.77</td></tr><tr><td>PDQ Total</td><td>14.4&#x000a0;&#x000b1;&#x000a0;4.4</td><td>14.2&#x000a0;&#x000b1;&#x000a0;4.3</td><td>0.52</td><td>15.2&#x000a0;&#x000b1;&#x000a0;5.8</td><td>14.6&#x000a0;&#x000b1;&#x000a0;5.6</td><td>0.32</td></tr><tr><td>PHQ9 Total</td><td>7.8&#x000a0;&#x000b1;&#x000a0;5.1</td><td>5.8&#x000a0;&#x000b1;&#x000a0;5.5</td><td>
<bold><italic>0.011</italic></bold>
</td><td>7.2&#x000a0;&#x000b1;&#x000a0;4.2</td><td>5.9&#x000a0;&#x000b1;&#x000a0;4.1</td><td>0.14</td></tr><tr><td>pirs20 Total</td><td>9.1&#x000a0;&#x000b1;&#x000a0;2.4</td><td>7.2&#x000a0;&#x000b1;&#x000a0;3.5</td><td>
<bold><italic>0.004</italic></bold>
</td><td>9.1&#x000a0;&#x000b1;&#x000a0;2.1</td><td>7.5&#x000a0;&#x000b1;&#x000a0;3.9</td><td>0.070</td></tr><tr><td>EQ5D Index</td><td>0.75&#x000a0;&#x000b1;&#x000a0;0.15</td><td>0.72&#x000a0;&#x000b1;&#x000a0;0.16</td><td>0.23</td><td>0.79&#x000a0;&#x000b1;&#x000a0;0.13</td><td>0.76&#x000a0;&#x000b1;&#x000a0;0.16</td><td>0.49</td></tr></tbody></table><table-wrap-foot><p>Values presented as Mean&#x000a0;&#x000b1;&#x000a0;SD. <italic>p</italic>-values: paired <italic>t</italic> test</p><p>Bold values are statistically significant <italic>p</italic> &#x0003c; 0.05</p></table-wrap-foot></table-wrap>
</p><p id="Par40">Per protocol analysis, i.e. only using patients who did complete treatment, is shown in Table <xref rid="Tab5" ref-type="table">5</xref>. One subject in the control group who had started using a sleeping agent was excluded. A significant improvement in ISI (<italic>p</italic>&#x000a0;=&#x000a0;0.002), ESS (<italic>p</italic>&#x000a0;=&#x000a0;0.042), PIRS20 (<italic>p</italic>&#x000a0;=&#x000a0;0.005) and PHQ-9 (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) scores were observed in the treatment group. In addition, the change in ISI was significantly greater in the treatment group (&#x02212;7.9&#x000a0;&#x000b1;&#x000a0;4.5) compared to controls (&#x02212;3.5&#x000a0;&#x000b1;&#x000a0;3.9) (<italic>p</italic>&#x000a0;=&#x000a0;0.033).<table-wrap id="Tab5"><label>Table 5</label><caption><p>Baseline and endpoint scores Per Protocol Analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">Case(<italic>N</italic>&#x000a0;=&#x000a0;14)</th><th colspan="4">Control(<italic>N</italic>&#x000a0;=&#x000a0;14)</th></tr><tr><th>Factor</th><th>n</th><th>Baseline</th><th>Endpoint</th><th>
<italic>P</italic> value</th><th>n</th><th>Baseline</th><th>Endpoint</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>ESS Total</td><td>8</td><td>11.1&#x000a0;&#x000b1;&#x000a0;4.9</td><td>8.4&#x000a0;&#x000b1;&#x000a0;5.9</td><td>
<bold><italic>0.042</italic></bold>
</td><td>12</td><td>9.8&#x000a0;&#x000b1;&#x000a0;6.2</td><td>9.0&#x000a0;&#x000b1;&#x000a0;4.5</td><td>0.40</td></tr><tr><td>FSS Total</td><td>8</td><td>27.3&#x000a0;&#x000b1;&#x000a0;13.1</td><td>21.3&#x000a0;&#x000b1;&#x000a0;11.0</td><td>0.21</td><td>12</td><td>30.5&#x000a0;&#x000b1;&#x000a0;11.5</td><td>28.2&#x000a0;&#x000b1;&#x000a0;11.2</td><td>0.35</td></tr><tr><td>ISI Total</td><td>8</td><td>15.7&#x000a0;&#x000b1;&#x000a0;3.0</td><td>7.8&#x000a0;&#x000b1;&#x000a0;4.4</td><td>
<bold><italic>0.002</italic></bold>
</td><td>12</td><td>15.3&#x000a0;&#x000b1;&#x000a0;3.0</td><td>12.2&#x000a0;&#x000b1;&#x000a0;5.5</td><td>
<bold><italic>0.033</italic></bold>
</td></tr><tr><td>UPDRS1b Total</td><td>8</td><td>9.8&#x000a0;&#x000b1;&#x000a0;4.0</td><td>6.9&#x000a0;&#x000b1;&#x000a0;3.1</td><td>
<bold><italic>0.004</italic></bold>
</td><td>12</td><td>9.7&#x000a0;&#x000b1;&#x000a0;1.8</td><td>8.6&#x000a0;&#x000b1;&#x000a0;2.4</td><td>
<bold><italic>0.037</italic></bold>
</td></tr><tr><td>UPDRS1b Modified</td><td>8</td><td>5.4&#x000a0;&#x000b1;&#x000a0;3.4</td><td>4.4&#x000a0;&#x000b1;&#x000a0;2.1</td><td>0.35</td><td>12</td><td>5.4&#x000a0;&#x000b1;&#x000a0;1.7</td><td>4.8&#x000a0;&#x000b1;&#x000a0;1.6</td><td>0.77</td></tr><tr><td>UPDRS2 total</td><td>8</td><td>12.6&#x000a0;&#x000b1;&#x000a0;7.9</td><td>12.3&#x000a0;&#x000b1;&#x000a0;6.3</td><td>0.93</td><td>12</td><td>10.9&#x000a0;&#x000b1;&#x000a0;7.1</td><td>10.6&#x000a0;&#x000b1;&#x000a0;8.4</td><td>0.99</td></tr><tr><td>PDQ Total</td><td>7</td><td>14.4&#x000a0;&#x000b1;&#x000a0;4.4</td><td>13.7&#x000a0;&#x000b1;&#x000a0;3.7</td><td>0.53</td><td>11</td><td>15.6&#x000a0;&#x000b1;&#x000a0;5.8</td><td>13.1&#x000a0;&#x000b1;&#x000a0;3.8</td><td>0.73</td></tr><tr><td>PHQ9 Total</td><td>8</td><td>7.8&#x000a0;&#x000b1;&#x000a0;5.1</td><td>3.5&#x000a0;&#x000b1;&#x000a0;4.5</td><td>
<bold><italic>0.005</italic></bold>
</td><td>12</td><td>7.5&#x000a0;&#x000b1;&#x000a0;4.2</td><td>5.4&#x000a0;&#x000b1;&#x000a0;3.3</td><td>0.17</td></tr><tr><td>pirs20 Total</td><td>8</td><td>9.1&#x000a0;&#x000b1;&#x000a0;2.4</td><td>5.0&#x000a0;&#x000b1;&#x000a0;2.3</td><td>
<bold><italic>&#x0003c;0.001</italic></bold>
</td><td>12</td><td>9.2&#x000a0;&#x000b1;&#x000a0;2.1</td><td>7.4&#x000a0;&#x000b1;&#x000a0;3.9</td><td>0.14</td></tr><tr><td>EQ5D Index</td><td>8</td><td>0.75&#x000a0;&#x000b1;&#x000a0;0.15</td><td>0.71&#x000a0;&#x000b1;&#x000a0;0.17</td><td>0.24</td><td>12</td><td>0.79&#x000a0;&#x000b1;&#x000a0;0.13</td><td>0.77&#x000a0;&#x000b1;&#x000a0;0.17</td><td>0.55</td></tr></tbody></table><table-wrap-foot><p>Values presented as Mean&#x000a0;&#x000b1;&#x000a0;SD. <italic>p</italic>-values: paired <italic>t</italic> test</p><p>Bold values are statistically significant <italic>p</italic> &#x0003c; 0.05</p></table-wrap-foot></table-wrap>
</p><p id="Par41">Five patients had a change in their medication during the trial. Two patients in the control group reported a decrease in their PD regimen, which they felt may have helped their sleep. One patient in the control group started taking a sleeping aid. Two patients (1 in treatment and 1 in control) had an increase in antidepressant medications.</p></sec><sec id="Sec6"><title>Discussion</title><p id="Par42">The etiology of insomnia in PD is heterogeneous and may arise from motor and non-motor features of PD such as nocturnal akinesia, nocturnal dystonia, wearing off, dyskinesias, nocturia, depression, anxiety, dementia, medications, punding, as well as primary sleep disorders [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. We performed the first randomized control trial to compare the effectiveness of web-based CBT-I compared to standard recommendations for insomnia in the PD population. While no significant difference in insomnia severity, as measured by the ISI, was found in the ITT analysis (likely due to the high drop out rate in the CCBT-I group), the <italic>per protocol</italic> analysis, amongst patients who finished the study, found significant improvement in insomnia symptoms with the CCBT-I than standard sleep hygiene education. Consistent with the improvement in ISI, subjects treated with CCBT-I also experienced significant increases in sleep efficiency that persisted to the final assessment at 12&#x000a0;weeks. As mentioned earlier, there are very few studies that evaluated the treatment of sleep in PD patients.</p><p id="Par43">Finally, statistically significant improvements in insomnia scores observed in the control group, after receiving standard written sleep hygiene recommendations, supporting the value of simple sleep education in clinical practice. However, the degree of improvement in the ISI score was not more than 6 points to consider clinically significant improvement. This suggests that more effective treatment is still in need.</p><p id="Par44">The major limitation of the study, in addition to the open-label nature of the treatment assignment, is the high dropout rate in PD population as this group had a difficult time completing the program. Dropout rates are variable across all PD clinical trials and can be up to 50%. A recently published meta-analysis on self-help CBT (via booklet, videotape, audiotape or internet) for insomnia reported an average dropout rate of 14.5% compared to 16.7% in therapist-administered CBT [<xref ref-type="bibr" rid="CR33">33</xref>]. Our dropout rate was about 43%. While all patients had computer access, they were not used to using it on regular basis. The average age of our population was 64&#x000a0;years old, which is roughly 10&#x02013;20&#x000a0;years older than prior studies that evaluated this tool for treatment for insomnia. A younger population may be more comfortable using a computer on a daily basis and therefore may achieve a higher success rate, compared to the average PD patient. Indeed, when we asked patients what were the barriers of CCBT-I that limited them from completing the program, most of them felt that the program interrupted their normal lifestyle. Patients were unable to keep up with daily logs and would have a tendency to forget to log on to computer to complete the tasks. Nonetheless, the difference in improvement of ISI scores in the <italic>intention-to-treat</italic> versus the <italic>per-protocol</italic> cohort suggests that CCBT-I treatment is only effective if patients carry it through all the way to the end.</p><p id="Par45">This can be challenging for PD patients due to difficult time keeping up with daily logs and it may be helpful to decrease logging frequency to once a week. In addition, one on-line CBT-I study found that compared to physician-referred participants (46.7%), community-recruited participants were significantly less likely to drop-out (18.2%) suggesting that community based recruitment may have higher levels of pre-treatment motivation or more comfortable with technology [<xref ref-type="bibr" rid="CR15">15</xref>]. In addition, we can consider refining the program to tailor to the unique needs PD patients, such as permitting a brief afternoon nap, if needed, to address fatigue and modification of sleep restriction and other behavioral strategies that may be more difficult for individuals with comorbid chronic health issues. The addition of periodic semi-structured video-chats or phone calls with trained personnel to monitor progress and problem-solve issues with the online program would likely decrease participant drop out as well as increase program efficacy.</p><p id="Par46">In addition, 5 patients did have a change in their medication during the study. One patient, who added a sleep aid, was removed from the analysis. Changes in PD medications as well as antidepressants can certainly aid in improving sleep; however, these changes were done for PD management and treatment of depression, not necessarily to treat insomnia. Any benefit patients received in sleep is consistent with the theory that insomnia in PD population is heterogeneous and many factors are contributory.</p><p id="Par47">Our observations expand the existing literature on the use of CCBT-I in clinical practice, examining its feasibility and effectiveness in an older cohort of PD patients with motor and non-motor impairments. Larger studies, with perhaps a more thoughtful construction of behavioral therapy execution and greater vigilance of its compliance, are needed to definitively compare the effectiveness on different types of insomnia therapies in PD patients.</p></sec><sec id="Sec7"><title>Conclusions</title><p id="Par48">This pilot study suggest that CCBT-I can be an effective treatment option for PD patients with insomnia when the course is thoroughly completed. High drop-out rate in our study shows that although effective, it may not be a generalizable option. We can tailor this program for the unique needs of PD patients and provide more trained personnel to monitor progress and problem-solve to increase program efficacy. However, larger studies are needed for further evaluation.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CBT-I</term><def><p id="Par5">Cognitive behavioral therapy for insomnia</p></def></def-item><def-item><term>CCBT-I</term><def><p id="Par6">
<italic>computerized</italic> cognitive behavioral therapy for insomnia</p></def></def-item><def-item><term>ESS</term><def><p id="Par7">Epworth Sleepiness Scale</p></def></def-item><def-item><term>FSS</term><def><p id="Par8">Fatigue Severity Scale</p></def></def-item><def-item><term>ISI</term><def><p id="Par9">Insomnia Severity Index</p></def></def-item><def-item><term>PD</term><def><p id="Par10">Parkinson Disease</p></def></def-item><def-item><term>PDQ8</term><def><p id="Par11">Parkinson Disease Questionnaire</p></def></def-item><def-item><term>PHQ-9</term><def><p id="Par12">Patient Health Questionnaire</p></def></def-item><def-item><term>PIRS20</term><def><p id="Par13">Pittsburgh Insomnia Rating Scale</p></def></def-item><def-item><term>RBD</term><def><p id="Par14">REM sleep behavior disorder</p></def></def-item><def-item><term>RLS</term><def><p id="Par15">Restless legs syndrome</p></def></def-item><def-item><term>TST</term><def><p id="Par16">total sleep time</p></def></def-item><def-item><term>UPDRS1b and II</term><def><p id="Par17">Unified Parkinson Disease Rating Scale 1b and II</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>The investigators would like to thank the Cleveland Clinic Wellness Institute for providing access to the Go! To Sleep program for subject participation. In addition, we would like to thank Parkinson&#x02019;s Pals for their continued support in education and research.</p><sec id="FPar1"><title>Funding</title><p id="Par49">Research and education funding from the Parkinson&#x02019;s Pals Organization.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par50">The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>SP assisted with research project conception, organization and execution, statistical analysis design and execution. He wrote the first draft of manuscript and made all edits with assistance. OO helped to recruit patients as well as execute study and assisted in reviewing and critiquing manuscript. GG and SO helped with designing the study and initial recruitment of patients. YH created and maintained database. TR helped with editing and revising manuscript. LW and JB were our statistical support for all analyses. MD, NF, AA, and HHF assisted with research project conception and organization along with statistical review and reviewing and critiquing final manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par51">This study was approved by Cleveland Clinic Institutional Review Board.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par52">We have obtained consent by all participants to publish data.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par53">Authors have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par54">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Chahine LM, Amara AW, Videnovic A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson&#x02019;s disease from 2005 to 2015. Sleep Med Rev. 2016. doi:10.1016/j.smrv.2016.08.001. [Epub ahead of print].</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>JP</given-names></name><name><surname>Tandberg</surname><given-names>E</given-names></name></person-group><article-title>Sleep disorders in patients with Parkinson&#x02019;s disease: epidemiology and management</article-title><source>CNS Drugs</source><year>2001</year><volume>15</volume><issue>4</issue><fpage>267</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.2165/00023210-200115040-00002</pub-id><pub-id pub-id-type="pmid">11463132</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oerlemans</surname><given-names>WG</given-names></name><name><surname>de Weerd</surname><given-names>AW</given-names></name></person-group><article-title>The prevalence of sleep disorders in patients with Parkinson&#x02019;s disease: a self-reported, community-based survey</article-title><source>Sleep Med</source><year>2002</year><volume>3</volume><fpage>147</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/S1389-9457(01)00127-7</pub-id><pub-id pub-id-type="pmid">14592234</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Factor</surname><given-names>SA</given-names></name><name><surname>McAlarney</surname><given-names>T</given-names></name><name><surname>Sanchez-Ramos</surname><given-names>JR</given-names></name><name><surname>Weiner</surname><given-names>WJ</given-names></name></person-group><article-title>Sleep disorders and sleep effect in Parkinson's disease</article-title><source>Mov Disord</source><year>1990</year><volume>5</volume><issue>4</issue><fpage>280</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1002/mds.870050404</pub-id><pub-id pub-id-type="pmid">2259351</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tandberg</surname><given-names>E</given-names></name><name><surname>Larsen</surname><given-names>JP</given-names></name><name><surname>Karlsen</surname><given-names>K</given-names></name></person-group><article-title>A community-based study of sleep disorders in patients with Parkinson&#x02019;s disease</article-title><source>Mov Disord</source><year>1998</year><volume>13</volume><fpage>895</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1002/mds.870130606</pub-id><pub-id pub-id-type="pmid">9827612</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP. Insomnia in Parkinson's disease: frequency and progression over time. J Neurol Neurosurg Psychiatry. 07;78(5):476&#x02013;479. Epub 2006 Nov 10.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>National Institutes of Health</collab></person-group><article-title>NIH state-of-the-science conference statement on manifestations and management of chronic insomnia in adults</article-title><source>NIH Consens State Sci Statements</source><year>2005</year><volume>22</volume><fpage>1</fpage><lpage>30</lpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Morin</surname><given-names>CM</given-names></name></person-group><source>Insomnia: psychological assessment and management</source><year>1993</year><publisher-loc>New York</publisher-loc><publisher-name>The Guilford Press</publisher-name></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bearnstein</surname><given-names>A</given-names></name><name><surname>Allexandre</surname><given-names>D</given-names></name><name><surname>Bena</surname><given-names>J</given-names></name><name><surname>Doyle</surname><given-names>J</given-names></name><name><surname>Gendy</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Fay</surname><given-names>S</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Moul</surname><given-names>D</given-names></name><name><surname>Foldvary-Schaefer</surname><given-names>N</given-names></name><name><surname>Roizen</surname><given-names>M</given-names></name><name><surname>Drerup</surname><given-names>M</given-names></name></person-group><article-title>&#x0201c;go! To sleep&#x0201d;: a web-based therapy for insomnia</article-title><source>Telemedicine and e-Health</source><year>2017</year><volume>23</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1089/tmj.2017.29001.crd</pub-id><pub-id pub-id-type="pmid">27991846</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritterband</surname><given-names>LM</given-names></name><name><surname>Thorndike</surname><given-names>FP</given-names></name><name><surname>Gonder-Frederick</surname><given-names>LA</given-names></name><name><surname>Magee</surname><given-names>JC</given-names></name><name><surname>Bailey</surname><given-names>ET</given-names></name><name><surname>Saylor</surname><given-names>DK</given-names></name><name><surname>Morin</surname><given-names>CM</given-names></name></person-group><article-title>Efficacy of an internet based behavioral intervention for adults with insomnia</article-title><source>Arch Gen Psychiatry</source><year>2009</year><volume>66</volume><fpage>692</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2009.66</pub-id><pub-id pub-id-type="pmid">19581560</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>SK</given-names></name><name><surname>Dizon</surname><given-names>J</given-names></name></person-group><article-title>Computerised cognitive behavioural therapy for insomnia: a systematic review and meta-analysis</article-title><source>Psychother Psychosom</source><year>2012</year><volume>81</volume><fpage>206</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1159/000335379</pub-id><pub-id pub-id-type="pmid">22585048</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Andrews G, Cuijpers P, Craske MG, McEvoy P, Titov N. Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. PLoS. 2010;5(10):e13196. doi:10.1371/journal.pone.0013196.</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Str&#x000f6;m</surname><given-names>L</given-names></name><name><surname>Pettersson</surname><given-names>R</given-names></name><name><surname>Andersson</surname><given-names>G</given-names></name></person-group><article-title>Internet-based treatment for insomnia: a controlled evaluation</article-title><source>J Consult Clin Psychol</source><year>2004</year><volume>72</volume><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1037/0022-006X.72.1.113</pub-id><pub-id pub-id-type="pmid">14756620</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>E</given-names></name><name><surname>Tsuchiya</surname><given-names>M</given-names></name><name><surname>Hirokawa</surname><given-names>K</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Mitsuhashi</surname><given-names>T</given-names></name><name><surname>Kawakami</surname><given-names>N</given-names></name></person-group><article-title>Evaluation of an internet-based self-help program for better quality of sleep among Japanese workers: a randomized controlled trial</article-title><source>J Occup Health</source><year>2008</year><volume>50</volume><fpage>387</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1539/joh.L7154</pub-id><pub-id pub-id-type="pmid">18716392</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>N</given-names></name><name><surname>Lewycky</surname><given-names>S</given-names></name></person-group><article-title>Logging on for better sleep: RCT of the effectiveness of online treatment for insomnia</article-title><source>Sleep</source><year>2009</year><volume>32</volume><fpage>807</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1093/sleep/32.6.807</pub-id><pub-id pub-id-type="pmid">19544758</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>WT</given-names></name><name><surname>Mihm</surname><given-names>P</given-names></name><name><surname>Behar</surname><given-names>A</given-names></name><name><surname>Morin</surname><given-names>CM</given-names></name></person-group><article-title>A computer device to deliver behavioral interventions for insomnia</article-title><source>Behav Sleep Med</source><year>2010</year><volume>8</volume><fpage>2</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1080/15402000903425314</pub-id><pub-id pub-id-type="pmid">20043245</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Ritterband LM, Bailey ET, Thorndike FP, Lord HR, Farrell-Carnahan L, Baum LD. Initial evaluation of an internet intervention to improve the sleep of cancer survivors with insomnia. Psychooncology. 2012;21(7):695&#x02013;705. doi:10.1002/pon.1969. Epub 2011 Apr 29.</mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Diederich NJ, McIntyre DJ. Sleep disorders in Parkinson's disease: many causes, few therapeutic options. Neurol Sci. 2012;314(1&#x02013;2):12&#x02013;19. doi:10.1016/j.jns.2011.10.025. Epub 2011 Nov 25. Review.</mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menza</surname><given-names>M</given-names></name><name><surname>Dobkin</surname><given-names>RD</given-names></name><name><surname>Marin</surname><given-names>H</given-names></name></person-group><article-title>Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo</article-title><source>Mov Disord</source><year>2010</year><volume>25</volume><fpage>1708</fpage><lpage>1714</lpage><pub-id pub-id-type="doi">10.1002/mds.23168</pub-id><pub-id pub-id-type="pmid">20589875</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juri</surname><given-names>C</given-names></name><name><surname>Chan&#x000e1;</surname><given-names>P</given-names></name><name><surname>Tapia</surname><given-names>J</given-names></name><name><surname>Kunstmann</surname><given-names>C</given-names></name><name><surname>Parrao</surname><given-names>T</given-names></name></person-group><article-title>Quetiapine for insomnia in Parkinson disease: results from an open-label trial</article-title><source>Clin Neuropharmacol</source><year>2005</year><volume>28</volume><fpage>185</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1097/01.wnf.0000174932.82134.e2</pub-id><pub-id pub-id-type="pmid">16062098</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medeiros</surname><given-names>CA</given-names></name><name><surname>Carvalhedo de Bruin</surname><given-names>PF</given-names></name><name><surname>Lopes</surname><given-names>LA</given-names></name><name><surname>Magalh&#x000e3;es</surname><given-names>MC</given-names></name><name><surname>de Lourdes Seabra</surname><given-names>M</given-names></name><name><surname>de Bruin</surname><given-names>VM</given-names></name></person-group><article-title>Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study</article-title><source>J Neurol</source><year>2007</year><volume>254</volume><fpage>459</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1007/s00415-006-0390-x</pub-id><pub-id pub-id-type="pmid">17404779</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Rios Romenets S, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, Postuma RB. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease - A randomized study. Parkinsonism Relat Disord. 2013. doi:10.1016/j.parkreldis.2013.03.003.</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991:50&#x02013;5.</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Moul DE, Pilkonis PA, Miewald JM, Carey TJ, Buysse DJ: Preliminary study of the test-retest reliability and concurrent validities of the Pittsburgh Insomnia Rating Scale (PIRS). Sleep 25 Abstract Supplement, A246-A247, 2002.</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>MT</given-names></name><name><surname>Wegener</surname><given-names>ST</given-names></name></person-group><article-title>Measures of sleep: the insomnia severity index, medical outcomes study (MOS) sleep scale, Pittsburgh sleep diary (PSD), and Pittsburgh sleep quality index (PSQI)</article-title><source>Arthritis Rheum</source><year>2003</year><volume>49</volume><issue>Suppl 5</issue><fpage>S184</fpage><lpage>S196</lpage><pub-id pub-id-type="doi">10.1002/art.11409</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krupp</surname><given-names>LB</given-names></name><name><surname>LaRocca</surname><given-names>NG</given-names></name><name><surname>Muir-Nash</surname><given-names>J</given-names></name><name><surname>Steinberg</surname><given-names>AD</given-names></name></person-group><article-title>The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosis</article-title><source>Arch Neurol</source><year>1989</year><volume>46</volume><fpage>1121</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1001/archneur.1989.00520460115022</pub-id><pub-id pub-id-type="pmid">2803071</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Kroenke K, Spitzer R, Williams W. The PHQ-9: Validy of a brief depression severity measure. JGIM. 2001:606&#x02013;16.</mixed-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkinson</surname><given-names>C</given-names></name><name><surname>Fitzpatrick</surname><given-names>R</given-names></name><name><surname>Peto</surname><given-names>V</given-names></name><name><surname>Greenhall</surname><given-names>R</given-names></name><name><surname>Hyman</surname><given-names>N</given-names></name></person-group><article-title><underline>The PDQ-8: development and validation of a short-form Parkinson&#x02019;s disease questionnaire</underline></article-title><source>Psychol Health</source><year>1997</year><volume>12</volume><issue>6</issue><fpage>805</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1080/08870449708406741</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Yang M, et al. Interpreting score differences in the insomnia severity index: using health-related outcomes to define the minimally important difference. Journal Curr Med Res Opin. 2009;25(10):2487&#x02013;94.</mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Bastien CH, Valli&#x000e8;res A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297&#x02013;307.</mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Adler CH, Thorpy MJ. Sleep issues in Parkinson's disease. Neurology. 2005;64(12 Suppl 3):S12&#x02013;20.</mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O. Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Eur J Neurol. 2005;12(3):199&#x02013;207.</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan-Yee Ho</surname><given-names>F</given-names></name><name><surname>Chung</surname><given-names>K-F</given-names></name><name><surname>Yeung</surname><given-names>W-F</given-names></name><etal/></person-group><article-title>Self-help cognitive-behavioral therapy for insomnia: A meta-analysis of randomized controlled trials</article-title><source>Sleep Med Rev</source><year>2015</year><volume>19</volume><fpage>17</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.smrv.2014.06.010</pub-id><pub-id pub-id-type="pmid">25104471</pub-id></element-citation></ref></ref-list></back></article>